Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Pes

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44347   clinical trials with a EudraCT protocol, of which   7375   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    28 result(s) found for: Pes. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2014-004474-42 Sponsor Protocol Number: V3_06082015 Start Date*: 2015-05-07
    Sponsor Name:Copenhagen University Hospital at Hvidovre
    Full Title: Treatment of equinus gait caused by dynamic tightening of the calf muscles in children with cerebral palsy. A randomized, placebo controlled Botulinum toxin type A volume/response study.
    Medical condition: Treatment of equinus gait caused by dynamic tightening of the calf muscles in children with cerebral palsy.
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004859 10015112 Equinus deformity of foot, acquired LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-005055-17 Sponsor Protocol Number: MRZ60201_3071_1 Start Date*: 2013-09-26
    Sponsor Name:Merz Pharmaceuticals GmbH
    Full Title: Open-label, non-controlled, multicenter long-term study to investigate the safety and efficacy of Xeomin® (incobotulinumtoxin A, NT 201) for the treatment of spasticity of the lower limb(s) or of c...
    Medical condition: Lower limb and combined lower limb and upper limb spasticity due to cerebral palsy
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004852 10058977 Spastic paresis LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: AT (Completed) EE (Completed) SK (Completed) CZ (Completed) Outside EU/EEA FR (Ongoing)
    Trial results: View results
    EudraCT Number: 2012-005054-30 Sponsor Protocol Number: MRZ60201_3070_1 Start Date*: 2013-04-08
    Sponsor Name:Merz Pharmaceuticals GmbH
    Full Title: Prospective, multicenter, randomized, double-blind, parallel-group, dose-response study of three doses Xeomin® (incobotulinumtoxinA, NT 201) for the treatment of lower limb spasticity in children a...
    Medical condition: Lower limb spasticity due to cerebral palsy
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004852 10058977 Spastic paresis LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: EE (Completed) AT (Completed) DE (Completed) SK (Completed) CZ (Completed) ES (Completed) Outside EU/EEA FR (Ongoing)
    Trial results: View results
    EudraCT Number: 2020-003688-25 Sponsor Protocol Number: INS1007-301 Start Date*: 2021-04-08
    Sponsor Name:Insmed Incorporated
    Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects with Non-Cystic Fibros...
    Medical condition: Non-Cystic Fibrosis Bronchiectasis
    Disease: Version SOC Term Classification Code Term Level
    23.0 10038738 - Respiratory, thoracic and mediastinal disorders 10083611 Non-cystic fibrosis bronchiectasis LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) PT (Completed) DK (Completed) NL (Completed) IE (Completed) HU (Completed) GR (Completed) PL (Completed) BG (Completed) LT (Prematurely Ended) SK (Completed) AT (Completed) FR (Completed) EE (Prematurely Ended) BE (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2018-002510-13 Sponsor Protocol Number: TROMBOFIBtrial Start Date*: 2018-09-28
    Sponsor Name:Antoni Sabaté Pes (Servicio de Anestesiología y Reanimación) del Hospital Universitari de Bellvitge
    Full Title: Impact of two thrombelastography-guided strategies of fibrinogen correction on blood product requirements in liver transplantation: a multicenter, randomized trial. TROMBOFIB trial
    Medical condition: Liver transplantation is a special risk situation for acute and severe bleeding determined by the complexity of the surgical procedure and by the alteration of haemostasis and coagulation factors, ...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004865 10024716 Liver transplantation LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-001639-35 Sponsor Protocol Number: M602011014 Start Date*: 2019-11-26
    Sponsor Name:Merz Pharmaceuticals GmbH
    Full Title: Prospective, randomized, double-blind, placebo-controlled, multicenter study to investigate the efficacy and safety of NT 201 in the treatment of lower limb spasticity caused by stroke or traumatic...
    Medical condition: Diagnosis of lower limb spasticity with or without upper limb spasticity of the same body side caused by stroke or traumatic brain injury
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004852 10058977 Spastic paresis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Trial now transitioned) DE (Trial now transitioned) FR (Trial now transitioned) NO (Completed) CZ (Trial now transitioned) GB (GB - no longer in EU/EEA) ES (Ongoing) IT (Trial now transitioned) HU (Trial now transitioned) SK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2008-002680-13 Sponsor Protocol Number: GNRH-PES Start Date*: 2010-11-18
    Sponsor Name:Fundacion para la Investigación "Hospital Universitario Doctor Peset"
    Full Title: “Antagonistas de GnRH en el manejo del cuerpo lúteo hemorrágico. Estudio clínico y ecográfico de la luteolisis mediada por el cetrorelix”
    Medical condition: Luteolisis o regresión del cuerpo lúteo.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10011117 Corpus luteum cyst or haematoma LLT
    Population Age: Adults Gender: Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2010-018454-13 Sponsor Protocol Number: SMB-NAL-III-09-1 Start Date*: 2010-08-31
    Sponsor Name:Laboratoires SMB S.A.
    Full Title: A Phase III, Multicentre, Randomised, Placebo-Controlled, Double Blind Study of the Incidence of Recurring Pulmonary Exacerbations in Cystic Fibrosis Patients using Two Different Doses of Inhaled N...
    Medical condition: Cystic fibrosis
    Disease: Version SOC Term Classification Code Term Level
    12.1 10011762 Cystic fibrosis PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) BE (Prematurely Ended) FR (Prematurely Ended) ES (Prematurely Ended) IT (Prematurely Ended) HU (Prematurely Ended) GB (Prematurely Ended) CZ (Prematurely Ended) DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-001634-18 Sponsor Protocol Number: M602011072 Start Date*: Information not available in EudraCT
    Sponsor Name:Merz Pharmaceuticals GmbH
    Full Title: A prospective, randomized, double-blind, placebo-controlled, two-stage, multicenter study with an open-label extension period to investigate the efficacy and safety of NT 201 in the treatment of lo...
    Medical condition: Pediatric lower limb (LL) spasticity (SP) caused by cerebral palsy (CP)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10041416 Spasticity LLT
    21.1 100000004852 10024132 Leg spasticity LLT
    20.1 100000004850 10021740 Infantile cerebral palsy LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: PL (Trial now transitioned) LV (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2024-000261-24 Sponsor Protocol Number: ECT-001-CB.007 Start Date*: 2024-06-24
    Sponsor Name:Cordex Biolohics Inc
    Full Title: A Phase I/II Open-Label Study of ECT-001-Expanded Cord Blood Transplantation in pediatric and young adult (<21year) Patients with High-Risk and Very High-Risk Myeloid Malignancies (ECT-001-CB.007)
    Medical condition: High-Risk and Very High-Risk Paediatric Myeloid Malignancies
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2009-018141-20 Sponsor Protocol Number: IN0901INT Start Date*: 2010-06-30
    Sponsor Name:LEO Pharma A/S
    Full Title: Eficacia y Seguridad del Tratamiento a Largo Plazo (6 meses) con Innohep® frente a Anticoagulación con un Antagonista de la Vitamina K (Warfarina) para el Tratamiento del Tromboembolismo Venoso Agu...
    Medical condition: Tromboembolismo venoso (TEV) en pacientes con cáncer activo.
    Disease: Version SOC Term Classification Code Term Level
    12.1 10066899 Venous thromboembolism LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) DE (Completed) SK (Completed) CZ (Completed) AT (Completed) PT (Completed) IT (Completed) DK (Completed) GR (Completed) LV (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2007-004614-14 Sponsor Protocol Number: BAY 59-7939/12839 Start Date*: 2007-12-05
    Sponsor Name:Bayer HealthCare AG
    Full Title: MAGELLaN - Multicenter, rAndomized, parallel Group Efficacy and safety study for the prevention of venous thromboembolism in hospitalized medically iLL patients comparing rivaroxabAN with enoxaparin
    Medical condition: Prevention of venous thromboembolism in patients who have been hospitalized for a medical illness
    Disease: Version SOC Term Classification Code Term Level
    9.1 10012108 Deep venous thrombosis prophylaxis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DE (Completed) FR (Completed) DK (Completed) LT (Completed) GB (Completed) BE (Completed) AT (Completed) NL (Completed) ES (Completed) GR (Completed) PT (Completed) SI (Completed) SK (Completed) CZ (Completed) IT (Completed) PL (Completed) LV (Completed) FI (Completed) HU (Completed) EE (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2008-006866-27 Sponsor Protocol Number: 1160.88 Start Date*: 2012-03-15
    Sponsor Name:Boehringer Ingelheim (Canada) Ltd./Ltée
    Full Title: Open-label safety and tolerability study of dabigatran etexilate given for 3 days at the end of standard anticoagulant therapy in children aged 12 years to less than 18 years
    Medical condition: Venous Thrombotic Event
    Disease: Version SOC Term Classification Code Term Level
    14.1 10047065 - Vascular disorders 10066899 Venous thromboembolism LLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2012-001836-72 Sponsor Protocol Number: ISIS416858-CS3 Start Date*: 2013-01-11
    Sponsor Name:Isis Pharmaceuticals, Inc.
    Full Title: An Open-label, Randomized, Active Comparator-Controlled, Adaptive Parallel-group Phase 2 Study to Assess the Safety and Efficacy of Multiple Doses of ISIS 416858 Administered Subcutaneously to Pati...
    Medical condition: Prophylaxis of venous thromboembolism (VTE) in patients undergoing total knee arthroplasty (TKA)
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004865 10049909 Venous thromboembolism prophylaxis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2017-004878-34 Sponsor Protocol Number: ATR-101-202 Start Date*: 2018-09-18
    Sponsor Name:Millendo Therapeutics, Inc.
    Full Title: A Multicenter Dose-Titration Open-Label Study of Nevanimibe Hydrochloride for the Treatment of Classic Congenital Adrenal Hyperplasia
    Medical condition: Classic Congenital Adrenal Hyperplasia
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10010323 Congenital adrenal hyperplasia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-006861-39 Sponsor Protocol Number: GH001-BD-202 Start Date*: 2022-06-20
    Sponsor Name:GH Research Ireland Limited
    Full Title: A Phase 2 Clinical Trial of GH001 in Patients with Bipolar II Disorder and a Current Major Depressive Episode (GH001-BD-202)
    Medical condition: Bipolar II Disorder
    Disease: Version SOC Term Classification Code Term Level
    26.1 10037175 - Psychiatric disorders 10026753 Manic and bipolar mood disorders and disturbances HLGT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Prematurely Ended) DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2016-003633-26 Sponsor Protocol Number: LYC-30937-2002 Start Date*: 2017-01-17
    Sponsor Name:Lycera Corp.
    Full Title: A MULTICENTER OPEN-LABEL EXTENSION STUDY TO ASSESS THE SAFETY AND TOLERABILITY OF LYC-30937-EC IN SUBJECTS WITH ACTIVE ULCERATIVE COLITIS
    Medical condition: Ulcerative Colitis
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004856 10045365 Ulcerative colitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended) HU (Prematurely Ended) CZ (Completed) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-002968-40 Sponsor Protocol Number: VX17-661-116 Start Date*: 2018-06-28
    Sponsor Name:Vertex Pharmaceuticals Incorporated
    Full Title: A Phase 3, Open-label, Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment With Tezacaftor in Combination With Ivacaftor in Subjects With Cystic Fibrosis Aged 6 Years and Olde...
    Medical condition: Cystic Fibrosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10011762 Cystic fibrosis PT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) IE (Completed) BE (Completed) DE (Completed) FR (Completed) DK (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2021-000050-26 Sponsor Protocol Number: AV-951-20-304 Start Date*: 2021-11-11
    Sponsor Name:AVEO Pharmaceuticals, Inc.
    Full Title: TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination with Nivolumab to Tivozanib Monotherapy in Subjects with Renal Cell Carcinoma Who Have...
    Medical condition: Renal Cell Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10050076 Metastatic renal carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) CZ (Trial now transitioned) FR (Trial now transitioned) BE (Trial now transitioned) PT (Trial now transitioned) PL (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-002860-31 Sponsor Protocol Number: ATI-450-RA-202 Start Date*: 2022-07-07
    Sponsor Name:Aclaris Therapeutics, Inc.
    Full Title: A Phase 2b, Randomized, Multicenter, Double-blind, Parallel Group, Placebo Controlled, Dose Ranging Study to Investigate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics ...
    Medical condition: Patients with Moderate to Severe Active Rheumatoid Arthritis (RA) who have had an Inadequate Response to MTX Alone
    Disease: Version SOC Term Classification Code Term Level
    23.1 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) BG (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun Jul 06 19:36:53 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA